APA (7th ed.) Citation

Martin, T., Dimopoulos, M., Mikhael, J., Yong, K., Capra, M., Facon, T., . . . Moreau, P. (2023, September). Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer Journal.

Chicago Style (17th ed.) Citation

Martin, Thomas, et al. "Correction: Isatuximab, Carfilzomib, and Dexamethasone in Patients with Relapsed Multiple Myeloma: Updated Results from IKEMA, a Randomized Phase 3 Study." Blood Cancer Journal Sep. 2023.

MLA (9th ed.) Citation

Martin, Thomas, et al. "Correction: Isatuximab, Carfilzomib, and Dexamethasone in Patients with Relapsed Multiple Myeloma: Updated Results from IKEMA, a Randomized Phase 3 Study." Blood Cancer Journal, Sep. 2023.